Biologic therapies for the treatment of chronic spontaneous urticaria (CSU) are potentially underutilized in veterans. Alisha Bridges Talks Patient Advocacy and Plaque & Scalp Psoriasis on Skin of Color Around 70% of patients presenting to the emergency department for urticaria received diphenhydramine. A study described the global, regional, and national atopic dermatitis prevalence trends among children from 2000-2021. Dr. Amy McMichael Discusses Plaque Psoriasis on Skin of Color, Johnson & Johnson's VISIBLE Study. Early-onset atopic dermatitis (AD) is associated with higher rates of developing atopic March conditions. Racial and ethnic disparities negatively impact access to treatment for Black and Hispanic children with atopic dermatitis. The Urticaria Activity Score is commonly utilized in chronic spontaneous urticaria clinical trials. Acupuncture therapy as an adjunct to omalizumab was found to improve disease control and quality of life. Patient advocate and influencer Alisha Bridges talks about living with Plaque & Scalp Psoriasis as a person of color. Patients with CSU who utilized a digital telehealth platform reported improved quality-of-life scores. Dr. Amy McMichael discusses plaque psoriasis on skin of color and Johnson & Johnson's VISIBLE study. Urticaria raises the risk of ADHD, bipolar disorder, and schizophrenia. Dupilumab is a monoclonal antibody approved to treat atopic dermatitis in adolescents and children. Omalizumab is a safe and effective long-term treatment for CSU. Most respondents agreed a patient-centered definition would improve communication with providers. Nearly 50% of patients with chronic spontaneous urticaria are atopic, with atopy linked to increased risk of dermatographism, A recent study demonstrated significant associations between acute urticaria and cardiovascular comorbidities. Autoimmune mast cell activation test shows promise as a diagnostic tool for chronic spontaneous urticaria. The global prevalence of pediatric atopic dermatitis increased from 1990 to 2019.